Molecure Future Growth

Future criteria checks 2/6

Molecure is forecast to grow earnings and revenue by 1.4% and 46.1% per annum respectively. EPS is expected to decline by 2.8% per annum. Return on equity is forecast to be -56.6% in 3 years.

Key information

1.4%

Earnings growth rate

-2.8%

EPS growth rate

Pharmaceuticals earnings growth	21.3%
Revenue growth rate	46.1%
Future return on equity	-56.6%
Analyst coverage	Low
Last updated	27 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:1B1 - Analysts future estimates and past financials data (PLN Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	27	-23	N/A	5	2
12/31/2025	54	-25	N/A	16	2
12/31/2024	3	-28	N/A	-25	2
9/30/2024	2	-31	-61	-33	N/A
6/30/2024	2	-30	-67	-29	N/A
3/31/2024	2	-29	-55	-16	N/A
12/31/2023	4	-28	-57	-23	N/A
9/30/2023	9	-45	-53	-40	N/A
6/30/2023	8	-42	-41	-34	N/A
3/31/2023	8	-39	-48	-39	N/A
12/31/2022	8	-36	-44	-34	N/A
9/30/2022	2	-16	-36	-8	N/A
6/30/2022	2	-16	-38	-14	N/A
3/31/2022	2	-15	-37	-15	N/A
12/31/2021	1	-14	-32	-13	N/A
9/30/2021	124	63	63	47	N/A
6/30/2021	124	64	62	47	N/A
3/31/2021	125	67	67	56	N/A
12/31/2020	125	68	66	57	N/A
9/30/2020	2	-3	-31	-2	N/A
6/30/2020	2	-3	-32	-2	N/A
3/31/2020	2	-4	-38	-6	N/A
12/31/2019	2	-4	-42	-7	N/A
9/30/2019	2	-5	-43	-4	N/A
6/30/2019	2	-5	-41	-6	N/A
3/31/2019	1	-5	-36	-4	N/A
12/31/2018	1	-4	-32	-5	N/A
9/30/2018	1	-4	-28	-5	N/A
6/30/2018	2	-4	N/A	-2	N/A
3/31/2018	2	-2	N/A	-2	N/A
12/31/2017	1	-2	N/A	-1	N/A
9/30/2017	1	-3	N/A	-5	N/A
6/30/2017	1	-3	N/A	-4	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-2	N/A	-1	N/A
12/31/2015	1	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1B1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1B1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1B1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1B1's revenue (46.1% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 1B1's revenue (46.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1B1 is forecast to be unprofitable in 3 years.

Molecure Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

New minor risk - Profitability

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Molecure S.A., Annual General Meeting, May 31, 2023

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies